Misunderstanding of EXAS' advantages over other Tests is Opportunity
Read my or Earwaxisafuel's posts to understand why EXAS DNA molecular technology is a disruptive, superior technology while EPC's may not. My estimates are that that EXAS's diagnostic kits should sell 10-20 million a year in US and Europe IMHO (explained in earlier posts). The bashers helped me add to my large position last week at around $11.30. If you do your homework and some research, you should have a great opportunity with EXAS. Analysis is better than fanning undeserved fears. Also, look at who owns the stock, the background of management, financial funding, and insider purchases. This should be a great year or buyout for EXAS in my personal opinion.
The goal was to prevent a potential acquirer from bypassing management with a low ball offer. Conroy has indicated they will bring the test to market rather than agree to an unacceptable offer and they are in the process of implementing a plan to accomplish that.
Poison ills are generally designed to force the interested purchaser to negotiate with management and the BOD. It prevents an acquiror from launching an unfriendly tender offer. In EXAS' case I would prefer any acquiror approach management.